Results 131 to 140 of about 77,471 (339)

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Molecular landscape of borderline ovarian tumours: A systematic review

Open Medicine
Borderline ovarian tumours (BOTs) show intriguing characteristics distinguishing them from other ovarian tumours. The aim of the systematic review was to analyse the spectrum of molecular changes found in BOTs and discuss their significance in the ...
Sadlecki Pawel, Walentowicz-Sadlecka Malgorzata   +1 more
doaj   +1 more source

PIK3CA Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?

International Journal of Molecular Sciences
Gliomas are the most common and lethal malignant primary brain tumors in adults, associated with the highest number of years of potential life lost. The latest WHO classification for central nervous system tumors highlighted the need for new biomarkers of diagnosis, prognosis, and response to therapy.
Tomás, Ana, Pojo, Marta
openaire   +3 more sources

PIK3CA mutant tumors depend on oxoglutarate dehydrogenase

, 2019
Oncogenic PIK3CA mutations are found in a significant fraction of human cancers, but therapeutic inhibition of PI3K has only shown limited success in clinical trials.
Spardy, Nicole, Sabatini, David, Widlund, Hans, Cowley, Glenn, Asara, John, Moody, Susan, Hahn, William, Kıvanç Birsoy, Kory, Nora, Weir, Barbara, Aguirre, Andrew, Ilic, Nina, DeAngelo, Joseph, Pacold, Michael, Singh, Shambhavi, Tsherniak, Aviad, Vazquez, Francisca, Root, David, Freinkman, Elizaveta   +18 more
core   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

Journal of Experimental & Clinical Cancer Research, 2017
Background Parallel to complex alteration in molecular and cellular events, enrichment of cancer stem cells (CSC) contributes significantly in deliberation and maintenance of cisplatin resistance.
Bhushan Thakur, Pritha Ray
doaj   +1 more source

PIK3CA mutation subtypes.

, 2013
PIK3CA mutation subtypes.
Melissa C. Southey (89921), Elizabeth J. Williamson (421772), Dallas R. English (89920), Kristy Sanderson (421771), Christophe Rosty (245644), Mark A. Jenkins (108168), Graham G. Giles (89916), Mark Clendenning (245560), Rhiannon J. Walters (245562), Aung Ko Win (245555), Susan Parry (163034), Daniel D. Buchanan (245549), Joanne P. Young (163036), Michael D. Walsh (245558), John L. Hopper (89919)   +14 more
core   +1 more source

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma [PDF]

, 2016
Background Many urothelial carcinomas (UC) contain activating PIK3CA mutations. In telomerase-immortalized normal urothelial cells (TERT-NHUC), ectopic expression of mutant PIK3CA induces PI3K pathway activation, cell proliferation and cell migration ...
Alder, O, Hurst, C.D., Shnyder, SD, M. A. Knowles, L. Kettlewell, Ross, R.L., Kettlewell, L., R. L. Ross, Kettlewell, L, Ross, RL, Knowles, M.A., S. D. Shnyder, C. D. Hurst, Hurst, CD, O. Alder, Shnyder, Steven, McPherson, H.R., H. R. McPherson, Alder, O., McPherson, HR, Knowles, MA   +20 more
core   +2 more sources

Deep whole genome sequencing of epileptogenic brain lesions

Epilepsia, EarlyView.
Abstract Objective Malformations of cortical development and low‐grade epilepsy‐associated tumors often cause drug‐resistant lesional focal epilepsy (LFE) amenable to surgical treatment. Genetic testing of resected brain tissue can provide diagnostic and mechanistic information and may eventually support personalized treatment approaches.
Christian M. Boßelmann, Costin Leu, Lucas Hoffmann, Roland Coras, Katja Kobow, Hajo Hamer, Daniel Delev, Christian G. Bien, Thilo Kalbhenn, Tom Pieper, Till Hartlieb, Kerstin Becker, Lisa Ferguson, Robyn M. Busch, Peter Nürnberg, Imad Najm, Ingmar Blümcke, Dennis Lal   +17 more
wiley   +1 more source

Targeted inhibition of PIK3CA mutations in glioma cell models [PDF]

, 2020
Gliomas are the most common and lethal brain tumors in adults, with efficient therapies non-existent. PIK3CA mutations are potential therapeutic targets, described as early constitutive events in glioblastomas (GBM).
Tomás, Ana Catarina Serra
core